Treatment of myelodysplastic syndromes in the era of precision medicine and immunomodulatory drugs: a focus on higher-risk disease.
Journal Information
Full Title: J Hematol Oncol
Abbreviation: J Hematol Oncol
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Related Papers from Same Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
Data Sharing
Code Sharing
COI Disclosure
Evidence found in paper:
"Declarations Ethics approval and consent to participateNot applicable. Consent for publicationNot applicable. Competing interestsRM, REH, AB, EB, AN, AZ, and MM declare no relevant financial conflicts of interest in relation to this manuscript. Competing interests RM, REH, AB, EB, AN, AZ, and MM declare no relevant financial conflicts of interest in relation to this manuscript."
Funding Disclosure
Evidence found in paper:
"Funding This research received no funding."
Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025